Showing 6361-6370 of 9503 results for "".
- AbbVie Receives FDA Orphan Drug Designation for Humira for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativahttps://practicaldermatology.com/news/abbvie-receives-fda-orphan-drug-designation-for-humira-for-the-investigational-treatment-of-moderate-to-severe-hidradenitis-suppurativa/2458945/AbbVie announced that the FDA has granted Humira® (adalimumab) orphan drug designation for the investigational treatment of moderate-to-severe hidradenitis suppurativa (HS) (Hurley Stage II and Hurley Stage III disease), a painful, chronic inflammatory skin disease. AbbVie's su
- ASDS Releases Consensus Recommendations on Basal Cell Carcinomahttps://practicaldermatology.com/news/asds-releases-consensus-recommendations-on-basal-cell-carcinoma/2458947/An expert group of dermatologic surgeons appointed by the American Society for Dermatologic Surgery (ASDS) Board of Directors has developed the first-ever consensus recommendations on the treatment and management of basal cell carcinoma (BCC). According to the ASDS, the document is intend
- R. Scott Peterson Is New Head of Medical Affairs at SkinCeuticalshttps://practicaldermatology.com/news/r-scott-peterson-is-new-head-of-medical-affairs-at-skinceuticals/2458946/R. Scott Peterson, PhD has been named Head of Medical Affairs at SkinCeuticals. In his new role at SkinCeuticals, Dr. Peterson will lead the medical affairs team and expand regional scientific services to support the realization of the company's miss
- American Academy of Dermatology Donates Shade Structure to the Smithsonian's National Zoohttps://practicaldermatology.com/news/american-academy-of-dermatology-donates-shade-structure-to-the-smithsonians-national-zoo/2458948/The American Trail Amphitheatre at the Smithsonian’s National Zoo now has built-in sun protection, thanks to a shade structure donation from the American Academy of Dermatology (AAD). The shade structure, which shades the 250-person seating area at the seal and sea lion exhibit, will protec
- Murad Partners with AAD to Launch Shade America Programhttps://practicaldermatology.com/news/murad-partners-with-aad-to-launch-shade-america-program/2458951/Murad, Inc. partnered with the American Academy of Dermatology (AAD) to launch Shade America, a new program that will build shade structures in parks and playgrounds across America to provide shade from the sun’s harmful rays. Through the Shade America program, Murad’s goal is to prov
- Skin Cancer Screening Initiative from AAD: ‘Who's Got Your Back?'https://practicaldermatology.com/news/skin-cancer-screening-initiative-from-aad-whos-got-your-back/2458952/In recognition of Melanoma/Skin Cancer Detection and Prevention Month in May and Melanoma Monday, observed on May 4 this year, the American Academy of Dermatology (AAD) asks the public to consider “Who’s Got Your Back?” when it comes to applying sunscreen and examining skin for
- Benzac Acne Solutions Premieres “Insta-Dramedy” Webserieshttps://practicaldermatology.com/news/benzac-acne-solutions-premieres-insta-dramedy-webseries/2458955/Galderma Laboratories, L.P launched its first webisode series, “The Benzacs,” a teen insta-dramedy told through 15-second Instagram videos and more than 80 images and short videos. The webseries features the new over-the-counter (OTC) acne treatment Benzac® Acne Solutions, which c
- DEKA Receives Additional FDA Clearance for its Synchro REPLA:Y Laser Systemshttps://practicaldermatology.com/news/deka-receives-additional-fda-clearance-its-synchro-replay-laser-systems/2458960/DEKA M.E.L.A received additional FDA clearance for its Synchro REPLA:Y® family of Laser Systems, allowing for Maximum Power of 180W and a 24mm spot size, the largest available in the industry. The Synchro REPLA:Y® family of Laser Systems consists of three aesthetic workstati
- NanoViricides: Topical Anti-Herpes Treatment Dramatically Improves Clinical Symptoms in an Animal Modelhttps://practicaldermatology.com/news/nanoviricides-reports-that-its-topical-anti-herpes-treatment-dramatically-improves-clinical-symptoms-in-an-animal-model/2458963/NanoViricides, Inc., a nanomedicine company developing anti-viral drugs, reports dramatic improvement in clinical symptoms associated with herpes simplex virus infection in the recently completed studies in mice. The studies were performed in the la
- Merck's Pembrolizumab Demonstrates Positive Results in Phase III Study for Advanced Melanomahttps://practicaldermatology.com/news/mercks-pembrolizumab-demonstrates-positive-results-in-phase-iii-study-for-advanced-melanoma/2458959/Merck announced results from the randomized, pivotal Phase III study, KEYNOTE-006, in the treatment of unresectable advanced melanoma. In the study, pembrolizumab was statistically superior to ipilimumab for progression-free survival (PFS), overall survival (OS), and overall response rate (ORR).